Comparative Pharmacology
Head-to-head clinical analysis: NETROMYCIN versus TOBRAMYCIN SULFATE PHARMACY BULK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NETROMYCIN versus TOBRAMYCIN SULFATE PHARMACY BULK.
NETROMYCIN vs TOBRAMYCIN SULFATE (PHARMACY BULK)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Netromycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis in bacteria.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death. Bactericidal against Gram-negative aerobes.
4-6 mg/kg IV once daily for serious infections; 1.5-2 mg/kg IV every 8 hours for gram-negative infections. Administered as intravenous infusion over 30-60 minutes.
5-7 mg/kg IV q24h (extended-interval) or 1.5-2.5 mg/kg IV q8h (traditional dosing) for serious Gram-negative infections; adjust based on therapeutic drug monitoring.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours in adults with normal renal function, but may extend to 24-48 hours in patients with impaired renal function.
Terminal elimination half-life of 2–3 hours in patients with normal renal function; prolonged to 24–60 hours in anuria/end-stage renal disease. In neonates, half-life may be 4–12 hours depending on gestational age.
Renal excretion of unchanged drug accounts for 80-90% of elimination via glomerular filtration; biliary/fecal elimination is minimal (<5%).
Primarily renal excretion of unchanged drug via glomerular filtration; >90% of dose recovered in urine within 24 hours. Biliary/fecal elimination is minimal (<1%).
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic